F102 A Primer and Practical Approach to Cancer Checkpoint Inhibitors for the Dermatologist
DESCRIPTION
Novel cancer immunotherapies, specifically immune checkpoint inhibitors (CPIs), have recently emerged, redefining treatment paradigms in oncology. However, CPIs present significant complications, with pruritus and skin-related toxicities being among the most common adverse effects. These issues necessitate a new skill set for practitioners caring for cancer patients receiving this class of medication. This session aims to enhance dermatology practitioners' knowledge of the underlying science of cancer immunotherapies, common adverse events and skin-related toxicities, and current NCCN guidelines alongside other management strategies for CPI-induced adverse events.
LEARNING OBJECTIVES
Summarize the science of the novel cancer immunotherapies called checkpoint inhibitors and their mechanisms of actions.
Discuss the current FDA-approved checkpoint inhibitor therapies and their uses in dermatology along with associated adverse events and dermatology-related toxicities.
Apply the NCCN guideline recommendations for the management of checkpoint inhibitor-related skin toxicities.
SCHEDULE
3:30 PM
Introduction and Overview of FDA-Approved Checkpoint Inhibitors with a Focus on NCCN Guideline Skin Cancer Indications
Oliver J. Wisco, DO, FAAD
3:40 PM
Q&A with Dr. Wisco
Oliver J. Wisco, DO, FAAD
3:45 PM
Overview of the Science of Cancer Checkpoint Inhibitors and the Mechanism of Action for Each Class
Jason Ezra Hawkes, MD, MS, FAAD
4:00 PM
Q&A with Dr. Hawkes
Jason Ezra Hawkes, MD, MS, FAAD
4:05 PM
Dermatologic Checkpoint Inhibitor Neoadjuvant Use
Michael Tetzlaff, MD, PhD
4:20 PM
Q&A with Dr. Tetzlaff
Michael Tetzlaff, MD, PhD
4:25 PM
Checkpoint Inhibitor Toxicity Incidence Overall and Correlation with Response with Concerns in Patients with Pre-Existing Skin Disease
Noah Io Hornick, MD, PhD, FAAD
4:40 PM
Q&A with Dr. Hornick
Noah Io Hornick, MD, PhD, FAAD
4:45 PM
Review of NCCN guidelines for Managing Checkpoint Inhibitor ADRs and Dermatology-Related Toxicities
Jennifer N. Choi, MD, FAAD
5:00 PM
Q&A with Dr. Choi
Jennifer N. Choi, MD, FAAD
5:05 PM
Case Discussions on Cutaneous Oncology Cases and Management of Checkpoint Inhibitor induced Dermatologic Toxicities
DIRECTOR
Oliver J. Wisco, DO, FAAD
SPEAKERS
Jennifer N. Choi, MD, FAAD
Jason Ezra Hawkes, MD, MS, FAAD
Noah Io Hornick, MD, PhD, FAAD
Michael Tetzlaff, MD, PhD
HANDOUTS
DISCLOSURES
Jennifer N. Choi, MD, FAAD
CeraVe/Valeante – Independent Contractor(Fees); Janssen Global Services, LLC – Advisory Board(Fees); La Roche-Posay Laboratorie Pharmaceutique – Advisory Board(Fees); OnQuality Pharmaceuticals, Ltd. – Advisory Board(Fees); PraHealth Sciences – Advisory Board(Fees); Pyxis Oncology – Advisory Board(Fees); Regeneron Pharmaceuticals, Inc. – Data Safety Monitoring Board(Fees);
Jason Ezra Hawkes, MD, MS, FAAD
AbbVie – Advisory Board(Fees), Investigator(Grants/Research Funding); Acelyrin – Investigator(Grants/Research Funding); Allakos – Investigator(Grants/Research Funding); Alumis – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Amgen – Investigator(Grants/Research Funding); Apogee Therapeutics – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Arcutis, Inc. – Advisory Board(Fees); Blueprint Medicines – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Bristol-Myers Squibb – Investigator(Grants/Research Funding); Celldex – Investigator(Grants/Research Funding); Concert Pharmaceuticals – Investigator(Grants/Research Funding); Eli Lilly and Company – Advisory Board(Fees), Investigator(Grants/Research Funding), Speaker(Honoraria); Galderma – Consultant (1099 relationship)(Fees), Speaker(Honoraria); Incyte – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Kymera Therapeutics – Investigator(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – Advisory Board(Honoraria), Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding), Speaker(Fees), Speaker(Honoraria); Novartis – Advisory Board(Fees), Consultant (1099 relationship)(Fees), Speaker/Faculty Education(Honoraria); Organon – Advisory Board(Honoraria), Speaker(Honoraria); Oruka Therapeutics – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Priovant Therapeutics – Investigator(Grants/Research Funding); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria), Consultant (1099 relationship)(Fees), Speaker(Honoraria), Stockholder(Stock); Sanofi Genzyme – Advisory Board(Honoraria), Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding), Speaker(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); UCB – Advisory Board(Honoraria), Consultant(Fees), Speaker(Honoraria);
Noah Io Hornick, MD, PhD, FAAD
HMP Education – Speaker(Honoraria); Regeneron – Advisory Board(Fees); Shook Hardy & Bacon – Consultant (1099 relationship)(Fees); Therakos, Inc. – Data Safety Monitoring Board(Fees);
Michael Tetzlaff, MD, PhD
Merck – Other(Fees); Philogen S.p.A. – Advisory Board(Fees); Regeneron – Advisory Board(Honoraria);
Oliver J. Wisco, DO, FAAD
Castle Biosciences – Investigator(Fees); Natera – Advisory Board(Fees); Regeneron – Consultant (1099 relationship)(Fees), Investigator(Fees);